Delivery Order SPE2DB20D1109-SPE2DB23FP23C

Award Date 5/30/23
Potential Completion Date 5/31/23
Potential Value $21K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of 4 milligram ondansetron hydrochloride tablets. The delivery order has a ceiling value of $3,615.57 and a completion date of February 10, 2025. It is placed under an Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor, for the supply of 4 mg ondansetron orally disintegrating tablets. The contract has a firm fixed price of $16,648.10 and a completion date of September 5, 2024. This delivery order is part of a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and the DLA Troop Support Medical, valued up to $999,999,999 through December...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of 4 mg Ondansetron Hydrochloride tablets. The contract has a firm fixed price, with a total ceiling value of $11,378.79, and runs through June 3, 2024. The contract is not designated as a set-aside. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $5,758.26, is for the delivery of 4,567,420,940 units of Ondansetron HCL 4 mg tablets. This delivery order is part of a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. The IDC...
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distribution company. The contract, valued at $3,553.71, is for the delivery of 4 mg ondansetron hydrochloride tablets to support military healthcare programs. The contract has an ultimate completion date of March 3, 2025 and is a firm fixed-price agreement. This delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the delivery of ondansetron ODT 4 mg tablets. The contract has a firm fixed price of $3,959.23 and a completion date of February 7, 2025. This appears to be a delivery order under a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. The...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $3,170.40, is for the delivery of 4 mg Ondansetron HCL tablets to support military healthcare programs. The contract has an ultimate completion date of December 12, 2023 and is a firm fixed-price contract. This delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at...
This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Ondansetron ODT 4 mg tablets. The contract has a firm fixed price of $6,946.82 and a completion date of January 14, 2025. This award is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with the DLA Troop Support Medical, which provides a comprehensive range of pharmaceutical products and...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of 8 mg ondansetron hydrochloride tablets. The contract has a ceiling value of $22,599.92 and an ultimate completion date of December 4, 2024. The contract is a firm fixed-price delivery order, with no set-aside designation, indicating open competition. AmerisourceBergen holds a significant Indefinite Delivery Contract (IDC) with the...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor, for the supply of 4 milligram Ondansetron orally disintegrating tablets in 30-count packages. The $2,715.52 firm-fixed-price contract has an ultimate completion date of August 12, 2024. This delivery order is part of a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and the DLA Troop Support Medical, valued at up to...
  • SPE2DB20D1109
    Indefinite Delivery Contract
  • SPE2DB20D1109-SPE2DB23FP23C
    Delivery Order

This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of 4 mg ondansetron hydrochloride tablets. The contract has a firm fixed price of $21,051.92 and a period of performance through May 31, 2023. This award is a child contract under a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. The IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. This specific delivery order does not have a set-aside designation, indicating open competition. The contract supports the provision of essential medications to military treatment facilities, veterans' healthcare programs, and other federal medical institutions.

Generated 2/27/25, 11:02 AM